Schulman IRB Adds Biosafety Officer to Team

CINCINNATI and DURHAM, N.C., Jan. 24, 2017 /PRNewswire/ -- Schulman IRB, the industry-leading central IRB in customer service and technology, announces that Daniel Eisenman, Ph.D., RBP, SM(NRCM), CBSP, has joined the organization as Biosafety Officer.

In his new role, Dr. Eisenman will work with Schulman leadership to develop and manage a forthcoming institutional biosafety committee (IBC) service. He will also provide consulting services for research organizations navigating the IBC landscape. The new IBC service represents Schulman's response to many requests from research sponsors and institutions seeking an independent option for establishing IBCs when required by federal regulations.

"We're delighted to work with someone so experienced and knowledgeable as Dr. Eisenman," said Michael Woods, President and CEO of Schulman IRB. "He has already built and managed several biosafety programs and worked with many IBCs. He has a knack for explaining complex concepts in a clear, understandable manner. All of this makes him the ideal leader for Schulman's IBC services."

Dr. Eisenman previously served as Biological Safety Officer, Alternate Responsible Official for CDC select agents, and Institutional Contact for Dual Use Research at the University of North Carolina Chapel Hill. He has served on multiple institutional biosafety committees and BSL-3 oversight committees as well as consulted for multiple IACUC committees.

Schulman's commercial IBC service will launch in the spring of 2017.

About Schulman IRB
Schulman IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services –including dedicated review capabilities for all phases of research across all therapeutic areas –to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services, offering comprehensive solutions to maximize the protection of human subjects and improve overall quality standards for clinical studies and data integrity. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).

For more information, please visit http://www.sairb.com or follow @SchulmanIRB on Twitter or on LinkedIn.

SOURCE Schulman IRB

Related Links

http://www.sairb.com